Regeneron Pharmaceuticals, Inc.
REGN
$680.03
-$7.77-1.13%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.61B | 3.44B | 3.03B | 3.22B | 3.22B |
| Total Other Revenue | 114.20M | 104.50M | 116.90M | 212.50M | 138.30M |
| Total Revenue | 3.72B | 3.55B | 3.15B | 3.43B | 3.36B |
| Cost of Revenue | 1.76B | 602.60M | 1.68B | 1.69B | 1.51B |
| Gross Profit | 1.96B | 2.94B | 1.46B | 1.74B | 1.85B |
| SG&A Expenses | 714.40M | 758.80M | 689.00M | 737.70M | 640.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 14.60M | 15.30M | -500.00K | -500.00K |
| Total Operating Expenses | 2.48B | 2.45B | 2.39B | 2.43B | 2.15B |
| Operating Income | 1.24B | 1.09B | 758.50M | 1.00B | 1.21B |
| Income Before Tax | 1.49B | 1.63B | 700.70M | 1.15B | 1.11B |
| Income Tax Expenses | 152.40M | 195.80M | -21.30M | -12.00M | 103.00M |
| Earnings from Continuing Operations | 1.34B | 1.43B | 722.00M | 1.16B | 1.01B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.34B | 1.43B | 722.00M | 1.16B | 1.01B |
| EBIT | 1.24B | 1.09B | 758.50M | 1.00B | 1.21B |
| EBITDA | 1.37B | 1.21B | 872.60M | 1.12B | 1.32B |
| EPS Basic | 12.40 | 13.25 | 6.70 | 10.88 | 9.48 |
| Normalized Basic EPS | 8.23 | 7.28 | 5.33 | 6.56 | 7.88 |
| EPS Diluted | 11.54 | 12.41 | 6.27 | 10.19 | 8.89 |
| Normalized Diluted EPS | 7.65 | 6.82 | 4.99 | 6.15 | 7.39 |
| Average Basic Shares Outstanding | 108.10M | 108.10M | 107.80M | 106.60M | 106.30M |
| Average Diluted Shares Outstanding | 116.20M | 115.40M | 115.10M | 113.80M | 113.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
